CS
KYMR icon

Candriam SCA’s Kymera Therapeutics KYMR Stock Holding History

Candriam SCA’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1M Sell
192,880
-8,792
-4% -$755K 0.1% 191
2026
Q1 		$16.8M Hold
201,672
– – 0.09% 216
2025
Q4 		$15.7M Buy
201,672
+10,033
+5% +$678K 0.08% 214
2025
Q3 		$10.8M Buy
191,639
+37,536
+24% +$1.69M 0.06% 261
2025
Q2 		$6.73M Buy
+154,103
New +$5.31M 0.04% 308
2024
Q4 		– Sell
-95,821
Closed -$4.54M – 694
2024
Q3 		$4.54M Sell
95,821
-142,344
-60% -$6.29M 0.03% 377
2024
Q2 		$7.11M Sell
238,165
-90,137
-27% -$3.12M 0.04% 294
2024
Q1 		$13.2M Sell
328,302
-15,000
-4% -$537K 0.08% 222
2023
Q4 		$8.74M Sell
343,302
-145,004
-30% -$2.59M 0.06% 268
2023
Q3 		$6.79M Hold
488,306
– – 0.05% 273
2023
Q2 		$11.2M Sell
488,306
-23,170
-5% -$664K 0.08% 234
2023
Q1 		$13.9M Hold
511,476
– – 0.1% 212
2022
Q4 		$12.8M Sell
511,476
-38,142
-7% -$1.02M 0.09% 225
2022
Q3 		$12M Buy
549,618
+79,758
+17% +$2.1M 0.08% 232
2022
Q2 		$9.25M Buy
469,860
+55,147
+13% +$1.29M 0.08% 236
2022
Q1 		$17.6M Buy
414,713
+11,894
+3% +$502K 0.12% 185
2021
Q4 		$25.6M Buy
402,819
+7,828
+2% +$456K 0.16% 147
2021
Q3 		$23.2M Sell
394,991
-16,000
-4% -$928K 0.16% 151
2021
Q2 		$19.9M Buy
410,991
+410,984
+5,871,200% +$17.8M 0.14% 176
2021
Q1 		$0 Buy
+7
New +$421 ﹤0.01% 811

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Candriam SCA's KYMR Position: Q2 2026 in Review

Candriam SCA reduced its Kymera Therapeutics (KYMR) stake by 4.4% in Q2 2026, selling an estimated $755K and leaving 192,880 shares worth $22.1M. The position accounts for 0.1% of the portfolio, ranked #191.

Candriam SCA first reported a position in KYMR in Q1 2021 and has held it in 20 quarters since. The position peaked at $25.6M in Q4 2021. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Candriam SCA held 192,880 shares of Kymera Therapeutics worth $22.1M as of Q2 2026.
  • Candriam SCA sold 8,792 Kymera Therapeutics shares in Q2 2026, an estimated $755K.
  • Kymera Therapeutics made up 0.1% of Candriam SCA's portfolio in Q2 2026, its #191 holding.
  • Candriam SCA first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Candriam SCA's Kymera Therapeutics position peaked at $25.6M in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.